QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:PZRX

PhaseRx (PZRX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free PZRX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.28
▼
$0.34
50-Day Range
$0.28
▼
$0.28
52-Week Range
$0.22
▼
$1.95
Volume
1.05 million shs
Average Volume
1.24 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About PhaseRx

PhaseRx, Inc. operates as a biopharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. Its product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency; argininosuccinate lyase deficiency; and argininosuccinate synthetase deficiency. The company was founded by Robert W. Overell, Patrick S. Stayton, Allan S. Hoffman, Oliver W. Press, and Paul H. Johnson on March 9, 2006 and is headquartered in Seattle, WA.

PZRX Stock News Headlines

April 14, 2024 | morningstar.com
Powszechny Zaklad Ubezpieczen SA PZU
June 21, 2023 | investing.com
Nimbus Group AB (BOAT)
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
May 15, 2023 | investing.com
PhaseRx (PZRXQ) Earnings Dates & Reports
September 16, 2022 | investing.com
Tongwei Co Ltd (600438)
September 13, 2022 | investing.com
DeNA Co Ltd (2432)
See More Headlines
Receive PZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2017
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PZRX
CUSIP
N/A
CIK
1429386
Web
phaserx.com
Phone
(206) 805-6300
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Steven H. Gillis Ph.D. (Age 63)
    Independent Chairman of the Board
  • Robert W. Overell Ph.D. (Age 61)
    President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director
  • Sean Monahan Ph.D.
    Vice President - Chemistry
  • Mary G. Prieve Ph.D.
    Vice President - Biology
  • Gordon Brandt M.D. (Age 57)
    Chief Medical Officer
  • James D. Watson
    Head of Corporate Development
  • Paul H. Johnson Ph.D. (Age 73)
    Director
  • Brian G. Atwood (Age 64)
    Independent Director
  • Michelle Renee Griffin (Age 51)
    Independent Director
  • Peggy V. Phillips (Age 63)
    Independent Director

Key Competitors

View All Competitors

PZRX Stock Analysis - Frequently Asked Questions

How were PhaseRx's earnings last quarter?

PhaseRx, Inc. (NASDAQ:PZRX) released its earnings results on Thursday, November, 9th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.14.

What other stocks do shareholders of PhaseRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseRx investors own include Avid Bioservices (CDMO), Immutep (IMMP), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Biocept (BIOC), Eleven Biotherapeutics (EBIO), Net Element (NETE), OHR Pharmaceutical (OHRP),

When did PhaseRx IPO?

PhaseRx (PZRX) raised $18 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 3,700,000 shares at a price of $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners served as the underwriters for the IPO.

This page (NASDAQ:PZRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes